The remarkable capacity of immunotherapies to induce durable regression in some patients
with metastatic cancer relies heavily on T cell recognition of tumor-presented antigens. As …

Pancreatic ductal adenocarcinoma (PDA) is among the most immune-resistant tumor types.
Its unique genomic landscape shaped by oncogenic drivers promotes immune suppression …

In 1986, Mosmann and Coffman identified 2 functionally distinct subsets of activated CD4 T
cells, Th1 and Th2 cells, being key in distinct T cell mediated responses. Over the past three …

It is unknown whether the human immune system frequently mounts a T cell response
against mutations expressed by common epithelial cancers. Using a next-generation …

Effective clinical cancer immunotherapies, such as administration of the cytokine IL-2,
adoptive cell transfer (ACT) and the recent success of blockade of the checkpoint …

Several current immunotherapy approaches target private neoantigens derived from
mutations that are unique to individual patients' tumors. However, immunotherapeutic …

The identification and characterization of tumor antigens are central objectives in developing
anti-cancer immunotherapy. Traditionally, tumor-associated antigens (TAAs) are considered …

Activating RAS missense mutations are among the most prevalent genomic alterations
observed in human cancers and drive oncogenesis in the three most lethal tumor types …

With the recent developments of adoptive T cell therapies and the use of new monoclonal
antibodies against the immune checkpoints, immunotherapy is at a turning point. Key …

While most of the focus in cancer immunology is on CD8+ cytotoxic T lymphocyte responses,
recent evidence indicates that CD4+ T cells are an equally critical component of the …